CompletedPhase 2

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

France61 participantsStarted 2005-12

Plain-language summary

The purpose of this study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease inhibitor naive HIV-1 patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Protease inhibitor naive patients * Wild type genotype * CD4 greater than 200/mm3 * Viral load between 10,000 copies/ml and 750,000 copies/ml * Signed informed consent Exclusion Criteria: * Pregnancy; breast feeding * Antiretroviral (ARV) pretreated patients * Hyperlipidemic treatment * Evolutive disease

What they're measuring

Virologic success defined as HIV RNA levels below 50 copies/ml after 16 weeks of initial treatment

Trial details

NCT IDNCT00122603

SponsorFrench National Agency for Research on AIDS and Viral Hepatitis

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More HIV Infections trials